thorium has been researched along with Cancer of Ovary in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Bruland, ØS; Bønsdorff, TB; Jorstad, IS; Juzeniene, A; Larsen, RH; Li, RG; Napoli, E; Westrøm, S | 1 |
Bjerke, RM; Cruciani, V; Cuthbertson, AS; Ellingsen, C; Golfier, S; Hagemann, UB; Hennekes, H; Karlsson, J; Kneip, C; Kristian, A; Mobergslien, A; Mumberg, D; Ryan, OB; Schatz, CA; Schuhmacher, J; Smeets, R; Uran, S; Wickstroem, K; Ziegelbauer, K | 1 |
Brevik, EM; Dahle, J; Heyerdahl, H; Røe, K | 1 |
3 other study(ies) available for thorium and Cancer of Ovary
Article | Year |
---|---|
Calcium Carbonate Microparticles as Carriers of
Topics: Alpha Particles; Animals; Calcium Carbonate; Drug Delivery Systems; Female; Mice; Ovarian Neoplasms; Particle Size; Radiopharmaceuticals; Radiotherapy Dosage; Radium; Thorium | 2021 |
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Lung Neoplasms; Mesothelin; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Radiopharmaceuticals; Thorium; Tissue Distribution; Xenograft Model Antitumor Assays | 2019 |
Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal, Humanized; Capillary Permeability; Contrast Media; Extracellular Space; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Plasma; Radioimmunotherapy; Random Allocation; Receptor, ErbB-2; Thorium; Time Factors; Transplantation, Heterologous; Trastuzumab | 2013 |